BioCentury
ARTICLE | Company News

Asklepios, Calimmune deal

February 1, 2016 8:00 AM UTC

Asklepios granted Calimmune rights to Asklepios’ adeno-associated virus (AAV) gene therapy technologies, which Calimmune plans to use in a Phase I/II trial of a gene therapy to treat osteoarthritis. A...